Kirkland & Ellis is advising Recipharm, a global contract development and manufacturing organisation (CDMO) and a portfolio company of EQT, on the acquisitions of Vibalogics, a virotherapy CDMO and Arranta Bio, a prominent advanced therapy CDMO. Vibalogics holds a leading position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services. Arranta Bio has established a strong microbiome platform with fermentation and purification expertise for naturally-derived and engineered bacteria consortia, complemented by services in analytics, proprietary media and cryopreservative formulations. Read the Vibalogics press release Read the Arranta Bio press release The Kirkland team was led by corporate partners Aneeq Durrani, Leo Greenberg, Roger Johnson, Michael Amalfe and Niklas Ahlklo and associates David Towarnicky, James Walker, Raisa Masud and Lawrence Ho; tax partners David Grenker and Tara Rhoades and associate Dana Quinn; and healthcare partner Katie Sullivan.